Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector
暂无分享,去创建一个
Harry E. Gruber | Joan M. Robbins | J. Hlavaty | N. Kasahara | H. Gruber | J. Robbins | D. Jolly | D. Ostertag | A. Lin | Noriyuki Kasahara | W. Gunzburg | Derek Ostertag | Karin K. Amundson | Fernando Lopez Espinoza | Bryan Martin | Taylor Buckley | Ana Paula Galvão da Silva | Amy H. Lin | David T. Valenta | Omar D. Perez | Carlos E. Ibañez | Ching-I Chen | Pär L. Pettersson | Ryan Burnett | Veronika Daublebsky | Juraj Hlavaty | Walter Gunzburg | Douglas J. Jolly | P. L. Pettersson | B. Martin | C. Ibañez | Ryan Burnett | K. Amundson | Fernando Lopez Espinoza | T. Buckley | Ching-I Chen | A. P. D. da Silva | O. Perez | Veronika Daublebsky | Derek Ostertag
[1] P. Cruz,et al. Scaleable purification process for gene therapy retroviral vectors , 2007, The journal of gene medicine.
[2] C. Richards,et al. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[3] B. Peterlin,et al. Enhanced replication and pathogenesis of Moloney murine leukemia virus in mice defective in the murine APOBEC3 gene. , 2009, Virology.
[4] J. Dichgans,et al. Characterization of Tu-2449, a glioma cell line derived from a spontaneous tumor in GFAP-v-src-transgenic mice: comparison with established murine glioma cell lines. , 1999, International journal of oncology.
[5] Albert Koong,et al. Impaired interferon signaling is a common immune defect in human cancer , 2009, Proceedings of the National Academy of Sciences.
[6] W. Wolf,et al. In vivo measurements of intratumoral metabolism, modulation, and pharmacokinetics of 5-fluorouracil, using 19F nuclear magnetic resonance spectroscopy. , 1991, Cancer research.
[7] M. Neuberger,et al. Mouse APOBEC3 Restricts Friend Leukemia Virus Infection and Pathogenesis In Vivo , 2008, Journal of Virology.
[8] Richard Assaker,et al. Local and Sustained Delivery of 5-Fluorouracil from Biodegradable Microspheres for the Radiosensitization of Malignant Glioma: A Randomized Phase II Trial , 2005, Neurosurgery.
[9] N. Rainov,et al. Clinical development of experimental virus-mediated gene therapy for malignant glioma. , 2011, Anti-cancer agents in medicinal chemistry.
[10] P. Musiani,et al. 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. , 1995, Journal of immunology.
[11] C. Tai,et al. Genomic Stability of Murine Leukemia Viruses Containing Insertions at the Env-3′ Untranslated Region Boundary , 2001, Journal of Virology.
[12] D. Jolly,et al. Factors affecting long-term expression of a secreted transgene product after intravenous administration of a retroviral vector. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[13] T. Pawlik,et al. Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. , 2001, Cancer research.
[14] D. Klatzmann,et al. Replicative retroviral vectors for cancer gene therapy , 2003, Cancer Gene Therapy.
[15] N. Nathanson,et al. Pathogenesis of West Nile Virus encephalitis in mice and rats. 1. Influence of age and species on mortality and infection. , 1967, American journal of epidemiology.
[16] J. Coffin,et al. Interactions of Murine APOBEC3 and Human APOBEC3G with Murine Leukemia Viruses , 2008, Journal of Virology.
[17] J. Stephenson,et al. Natural immunity in mice to structural polypeptides of endogenous type C RNA viruses , 1976, Journal of virology.
[18] H. Yoshiji,et al. Bystander effect caused by cytosine deaminase gene and 5-fluorocytosine in vitro is substantially mediated by generated 5-fluorouracil. , 1998, Anticancer research.
[19] R. Blaese,et al. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. , 1994, Cancer research.
[20] T. Kawase,et al. Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV , 2002, Cancer Gene Therapy.
[21] S. Russell,et al. History of oncolytic viruses: genesis to genetic engineering. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[22] D. Klatzmann,et al. Beyond oncolytic virotherapy: replication-competent retrovirus vectors for selective and stable transduction of tumors. , 2005, Current gene therapy.
[23] A. Rehemtulla,et al. Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fluorocytosine of human colorectal cancer xenografts. , 2000, Cancer research.
[24] K. Cichutek,et al. Cell entry targeting restricts biodistribution of replication-competent retroviruses to tumour tissue , 2008, Gene Therapy.
[25] G. Lenz,et al. In vivo glioblastoma growth is reduced by apyrase activity in a rat glioma model , 2006, BMC Cancer.
[26] M. Vähä-Koskela,et al. Novel oncolytic viruses: riding high on the next wave? , 2010, Cytokine & growth factor reviews.
[27] N. Imura,et al. Effects of methylmercury on mitotic mouse glioma cells. , 1978, Environmental research.
[28] T. Shono,et al. A comparative study of apoptosis and proliferation in germinoma and glioblastoma. , 2000, Neuro-oncology.
[29] R. Weissleder,et al. Fluorescent nanoparticle uptake for brain tumor visualization. , 2006, Neoplasia.
[30] K. Cornetta,et al. Amphotropic murine leukemia retrovirus is not an acute pathogen for primates. , 1990, Human gene therapy.
[31] Hui Yang,et al. Antitumor efficiency of the cytosine deaminase/5-fluorocytosine suicide gene therapy system on malignant gliomas: an in vivo study. , 2009, Medical science monitor : international medical journal of experimental and clinical research.
[32] A. Hagenbeek,et al. Human primary T lymphocytes have a low capacity to amplify MLV-based amphotropic RCR and the virions produced are largely noninfectious , 2003, Gene Therapy.
[33] G. Klein,et al. Immunological Tolerance of Neonatally Infected Mice to the Moloney Leukaemia Virus , 1966, Nature.
[34] Donald J Buchsbaum,et al. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. , 2002, Cancer research.
[35] R G Blasberg,et al. Noninvasive quantitation of cytosine deaminase transgene expression in human tumor xenografts with in vivo magnetic resonance spectroscopy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[36] A. Basu,et al. Microglial response to viral challenges: every silver lining comes with a cloud. , 2011, Frontiers in bioscience.
[37] M. Phelps,et al. Small-Animal PET/CT for Monitoring the Development and Response to Chemotherapy of Thymic Lymphoma in Trp53−/− Mice , 2010, The Journal of Nuclear Medicine.
[38] Brian Salmons,et al. Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma , 2011, Journal of Neuro-Oncology.
[39] W. Greene,et al. Innate Retroviral Restriction by Apobec3 Promotes Antibody Affinity Maturation In Vivo , 2010, The Journal of Immunology.
[40] D. Pardoll,et al. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[41] H. Atkins,et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. , 2003, Cancer cell.
[42] F. Errington,et al. The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. , 2009, Human gene therapy.
[43] J. E. Bennett,et al. Mode of action of 5-fluorocytosine. , 1978, Biochemical pharmacology.
[44] R. O’Neill,et al. Orthotopic transplantation of v-src-expressing glioma cell lines into immunocompetent mice: establishment of a new transplantable in vivo model for malignant glioma. , 2007, Journal of neurosurgery.
[45] Thomas C. Chen,et al. Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[46] J. Julien,et al. Innate immunity: the missing link in neuroprotection and neurodegeneration? , 2002, Nature Reviews Neuroscience.
[47] C. Tai,et al. Therapeutic efficacy of replication-competent retrovirus vector-mediated suicide gene therapy in a multifocal colorectal cancer metastasis model. , 2007, Cancer research.
[48] B. Stoddard,et al. Computational Thermostabilization of an Enzyme , 2005, Science.